Clinical pharmacotherapy and drug development for pulmonary arterial hypertension
| Autor: | Massimiliano Mulè, Corrado Tamburino, Marilena Scarabelli, Gian Paolo Ussia, Davide Capodanno |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
medicine.medical_specialty
Survival Hypertension Pulmonary Alternative medicine Disease Patents as Topic Quality of life (healthcare) Pharmacotherapy Drug Discovery polycyclic compounds Medicine Animals Humans Pharmacology (medical) Intensive care medicine Antihypertensive Agents Exercise Tolerance business.industry Standard treatment Exercise capacity Drug development Drug Design Physical therapy Quality of Life Cardiology and Cardiovascular Medicine business |
| Zdroj: | Scopus-Elsevier |
| Popis: | Pulmonary arterial hypertension (PAH) is a rare, but serious condition which, if untreated, is associated with a poor survival. Currently, even if several trials have led to the approval of many drugs for PAH, there is no established cure for this disease. However, approved drugs for PAH have contributed to significantly improve symptoms, exercise capacity, quality of life and survival of these patients. The aim of this review is to overview the standard treatment of PAH and to give some insights about new treatments that are currently under investigation along with the discussion of recent patents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|